"At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player in a global drama-a David to pharma's Goliaths-turning its technology toward breaking the global grip of the terrible...